Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04030455 · ClinicalTrials.gov registry record · Phase 2

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

A Phase 2 study of Laryngeal Squamous Cell Carcinoma and Stage III Laryngeal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT04030455 is a Phase 2 study of Laryngeal Squamous Cell Carcinoma and Stage III Laryngeal Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants, below the 94-participant average among 5 other Laryngeal Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04030455, a Phase 2 study of Laryngeal Squamous Cell Carcinoma and Stage III Laryngeal Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cisplatin, docetaxel, and pembrolizumab may help to control the disease.

Conditions Studied

Laryngeal Squamous Cell Carcinoma Stage III Laryngeal Cancer AJCC v8 Stage II Laryngeal Cancer AJCC v8

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Carboplatin
  • DRUG Docetaxel
  • DRUG Cisplatin

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2019-08-07
Est. Completion 2026-09-17
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04030455

The ClinicalTrials.gov registry entry for NCT04030455 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 5 other Laryngeal Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Laryngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT04030455 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04030455 about?

NCT04030455 is a clinical study titled "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer". This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping t...

What is the current status of trial NCT04030455?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-08-07. Estimated completion is 2026-09-17.

What conditions does trial NCT04030455 study?

This clinical trial studies the following conditions: Laryngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage II Laryngeal Cancer AJCC v8.

What interventions are being tested in trial NCT04030455?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Docetaxel (DRUG), Cisplatin (DRUG).

Who is sponsoring clinical trial NCT04030455?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04030455 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Laryngeal Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Laryngeal Squamous Cell Carcinoma

All registered trials for this condition

Stage III Laryngeal Cancer AJCC v8

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.